CTMXCytomX Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.77 · now $2.77 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CTMX has typically landed between $2.01 and $4.10 — a range of −27.5% to +47.9% from the issuance price $2.77.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,727 overlapping 1 month windows · 2015-10-082026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.77) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CTMX has typically landed a month from the 2026-09-16 close of $2.77 — the range is history, not a prediction.

$2.01worst · -27.5%$4.1best · +47.9%
  • now $2.77 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.68 (-3.3%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.32$3.04
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.01$4.1
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,727 windows spanning 2015-10-08 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-05-03−62.1%−62.1%+0.0%
2024-05-06−61.8%−61.8%+0.0%
2024-05-02−61.1%−62.2%+0.0%
3 best
2025-04-10+405.5%+0.0%+405.5%
2025-04-11+346.9%+0.0%+369.5%
2025-04-29+306.7%+0.0%+306.7%

2,727 overlapping windows · 2015-10-082026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~11 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
64%
+9.5%
n=11
Feb
36%
−2.9%
n=11
Mar
18%
−4.3%
n=11
Apr
45%
−1.7%
n=11
May
36%
+16.3%
n=11
Jun
45%
−2.9%
n=11
Jul
27%
−6.0%
n=11
Aug
45%
−0.7%
n=11
Sep
27%
+1.6%
n=11
Oct
30%
−7.0%
n=10
Nov
82%
+17.9%
n=11
Dec
45%
+0.4%
n=11

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$22026-06-15: 1 insider sale, $5K — Ogden Christopher2026-03-17: 4 insider sales, $1.2M — McCarthy Sean A., BELVIN MARCIA, Chu Yu-Waye, Ogden Christopher2025-11-06: 1 insider sale, $462K — McCarthy Sean A.2025-11: 1 open-market sale, $462K2026-03: 4 open-market sales, $1.2M2026-06: 1 open-market sale, $5K↑ buys↓ salesofficer Ogden Christopher — Sale on 2026-06-15, filed 2 days after the tradedirector McCarthy Sean A. — Sale on 2026-03-17, filed 2 days after the tradeofficer BELVIN MARCIA — Sale on 2026-03-17, filed 2 days after the tradeofficer Chu Yu-Waye — Sale on 2026-03-17, filed 2 days after the tradeofficer Ogden Christopher — Sale on 2026-03-17, filed 2 days after the tradedirector McCarthy Sean A. — Sale on 2025-11-06, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-06-15Ogden ChristopherofficerSale1,624 @ $3.05$5K−0.5% of holding+21.0%not yet — horizon still open295,324Form 4 · filed 2 days after the trade
2026-03-17McCarthy Sean A.directorSale118,969 @ $6.42$764K−9.9% of holding−15.2%−62.2%1,078,922Form 4 · filed 2 days after the trade
2026-03-17BELVIN MARCIAofficerSale31,492 @ $6.42$202K−9.5% of holding−15.2%−62.2%300,760Form 4 · filed 2 days after the trade
2026-03-17Chu Yu-WayeofficerSale21,279 @ $6.42$137K−10.1% of holding−15.2%−62.2%189,446Form 4 · filed 2 days after the trade
2026-03-17Ogden ChristopherofficerSale19,323 @ $6.42$124K−6.1% of holding−15.2%−62.2%296,948Form 4 · filed 2 days after the trade
2025-11-06McCarthy Sean A.directorSale101,793 @ $4.54$462K−9.3% of holding−9.6%−18.8%987,891Form 4 · filed 4 days after the trade
2025-06-16McCarthy Sean A.directorSale55,511 @ $2.69$149K−4.8% of holding−7.8%+54.3%1,089,684Form 4 · filed 1 day after the trade
2025-06-16BELVIN MARCIAofficerSale13,884 @ $2.69$37K−4.9% of holding−7.8%+54.3%272,252Form 4 · filed 1 day after the trade
2025-06-16Ogden ChristopherofficerSale10,614 @ $2.69$29K−4.5% of holding−7.8%+54.3%226,271Form 4 · filed 1 day after the trade
2025-06-13Ogden ChristopherofficerSale1,641 @ $2.95$5K−0.8% of holding−18.0%+37.5%199,385Form 4 · filed 4 days after the trade
2025-03-18McCarthy Sean A.directorSale37,656 @ $0.60$23K−3.6% of holding+10.3%+219.2%995,195Form 4 · filed 2 days after the trade
2025-03-18BELVIN MARCIAofficerSale19,512 @ $0.60$12K−7.3% of holding+10.3%+219.2%248,636Form 4 · filed 2 days after the trade
2025-03-18ROWLAND LLOYD AofficerSale10,203 @ $0.60$6K−7.8% of holding+10.3%+219.2%120,594Form 4 · filed 2 days after the trade
2025-03-18Ogden ChristopherofficerSale8,551 @ $0.60$5K−4.1% of holding+10.3%+219.2%201,026Form 4 · filed 2 days after the trade
2025-03-18Chu Yu-WayeofficerSale4,025 @ $0.60$2K−2.9% of holding+10.3%+219.2%135,725Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

58 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-03Carvajal AlejandraofficerAward / grant100,000100,000Form 4
2026-08-03Carvajal AlejandraofficerAward / grant450,000450,000Form 4
2026-07-24Fuchs Charles S.directorAward / grant118,000118,000Form 4
2026-06-17Gilbert Halley EdirectorAward / grant59,00059,000Form 4
2026-06-17Meyers James RdirectorAward / grant59,00059,000Form 4
2026-06-17Young Matthew P.directorAward / grant59,00059,000Form 4
2026-06-17Su ZhendirectorAward / grant59,00059,000Form 4
2026-06-17Mohindru ManidirectorAward / grant59,00059,000Form 4
2026-06-17Ashworth AlandirectorAward / grant59,00059,000Form 4
2026-06-17Jones Elaine VdirectorAward / grant59,00059,000Form 4
2026-02-02McCarthy Sean A.directorAward / grant210,0001,197,891Form 4
2026-02-02BELVIN MARCIAofficerAward / grant60,000332,252Form 4
2026-02-02BELVIN MARCIAofficerAward / grant250,000250,000Form 4
2026-02-02Ogden ChristopherofficerAward / grant325,000325,000Form 4
2026-02-02Ogden ChristopherofficerAward / grant90,000316,271Form 4
2026-02-02McCarthy Sean A.directorAward / grant980,000980,000Form 4
2026-02-02Chu Yu-WayeofficerAward / grant75,000210,725Form 4
2026-02-02Chu Yu-WayeofficerAward / grant300,000300,000Form 4
2026-02-02Lester RachaelofficerAward / grant20,00020,000Form 4
2026-02-02Lester RachaelofficerAward / grant50,00050,000Form 4
2025-10-20Lester RachaelofficerAward / grant650,000650,000Form 4
2025-09-26BELVIN MARCIAofficerAward / grant18,15018,150Form 4
2025-09-26Chu Yu-WayeofficerAward / grant87,50087,500Form 4
2025-09-26Chu Yu-WayeofficerAward / grant43,75043,750Form 4
2025-09-26Ogden ChristopherofficerAward / grant39,15039,150Form 4
2025-09-26McCarthy Sean A.directorAward / grant285,000285,000Form 4
2025-09-26Ogden ChristopherofficerAward / grant78,25078,250Form 4
2025-09-26McCarthy Sean A.directorAward / grant570,000570,000Form 4
2025-09-26BELVIN MARCIAofficerAward / grant36,30036,300Form 4
2025-06-13McCarthy Sean A.directorOption exercise150,0000Form 4
2025-06-13McCarthy Sean A.directorOption exercise150,0001,145,195Form 4
2025-06-13BELVIN MARCIAofficerOption exercise37,500286,136Form 4
2025-06-13Ogden ChristopherofficerOption exercise37,5000Form 4
2025-06-13BELVIN MARCIAofficerOption exercise37,5000Form 4
2025-06-13Ogden ChristopherofficerOption exercise37,500236,885Form 4
2025-06-11Mohindru ManidirectorAward / grant38,00038,000Form 4
2025-06-11Young Matthew P.directorAward / grant38,00038,000Form 4
2025-06-11Jones Elaine VdirectorAward / grant38,00038,000Form 4
2025-06-11Meyers James RdirectorAward / grant38,00038,000Form 4
2025-06-11Ashworth AlandirectorAward / grant38,00038,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.